FDA approves eculizumab for generalized myasthenia gravis
Yesterday the U.S. Food and Drug Administration (FDA) approved eculizumab as a treatment for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
Oct 25, 2017
0
4